Hemispherx offers more data on Ampligen

Hoping to overcome the FDA's concerns regarding Ampligen, Hemispherx announced that it has submitted new preclinical data for the drug to regulators. The agency had rejected Ampligen after concluding that the studies Hemispherx had mounted for the drug had not provided conclusive evidence of the drug's efficacy as a treatment for chronic fatigue syndrome. The FDA recommended that Hemispherx mount a major new trial involving at least 300 patients. And that decision capped 20 years of work on the drug. Report